Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new study shows waiting to treat patent ductus arteriosus in preterm infants improves survival and reduces complications compared to early drug therapy.
A new clinical trial published December 9, 2025, in the Journal of the American Medical Association found that a "wait and see" approach to patent ductus arteriosus (PDA) in extremely preterm infants leads to better survival rates than early drug treatment.
Among 482 infants born between 22 and 28 weeks, only 4% in the expectant management group died by 36 weeks postmenstrual age, compared to nearly 10% in those treated with indomethacin, ibuprofen, or acetaminophen.
The study found no survival benefit from early medication and identified increased risks of serious complications, including sepsis and intestinal tissue death, likely due to drug side effects.
These findings suggest that avoiding early intervention may be safer, prompting experts to recommend reconsidering current treatment practices and discussing observation-based strategies with doctors.
Un nuevo estudio muestra que esperar para tratar el ductus arterioso patente en bebés prematuros mejora la supervivencia y reduce las complicaciones en comparación con la terapia farmacológica temprana.